Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM). This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results